PFM Health Sciences’s Amgen AMGN Stock Holding History

PFM Health Sciences’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-831,900	Closed	-$153M	–	75
2019 Q2	$153M	Buy	+831,900	New	+$149M	2.91%	4

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PFM Health Sciences's AMGN Position: Q4 2024 in Review

PFM Health Sciences sold out of Amgen (AMGN) in Q4 2024, closing a stake of 90,297 shares — an estimated $29.1M sold.

PFM Health Sciences first reported a position in AMGN in Q4 2014 and held it in 3 quarters. The position peaked at $47.9M in Q4 2014. 2,855 funds tracked by Wall St. Rank hold AMGN as of Q4 2024.

PFM Health Sciences reported no remaining Amgen position as of Q4 2024 after selling out during the quarter.
PFM Health Sciences sold 90,297 Amgen shares in Q4 2024, an estimated $29.1M.
PFM Health Sciences first reported a position in Amgen in Q4 2014 and held it in 3 quarters.
PFM Health Sciences's Amgen position peaked at $47.9M in Q4 2014.
2,855 funds tracked by Wall St. Rank held Amgen as of Q4 2024.

Based on PFM Health Sciences's 13F filing for Q4 2024, filed 14 Feb 2025.